Arthur J. Smerling

Arthur J. Smerling

Auto-generated profile, based on publicly available information

Arthur J. Smerling

Division of Critical Care, Department of Pediatrics, Columbia University College of Physicians & Surgeons, Morgan Stanley Children's Hospital of New York, New York, New York

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JBJason R. Buckley
Jason R. Buckley
JCJohn M. Costello
John M. Costello
ASArthur J. Smerling
Arthur J. Smerling
PSPeter Sassalos
Peter Sassalos
VAVenu Amula
Venu Amula
CMChristopher W. Mastropietro
Christopher W. Mastropietro

1 February 2013 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
GWGarret M. Weber
Garret M. Weber
ASArthur J. Smerling
Arthur J. Smerling
JSJohn M. Saroyan
John M. Saroyan

1 May 1995 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
CLC. A. Lawson
C. A. Lawson
ASA. J. Smerling
A. J. Smerling
YNY. Naka
Y. Naka
DBD. Burkhoff
D. Burkhoff
MDM. L. Dickstein
M. L. Dickstein
DPD. J. Pinsky
D. J. Pinsky
Selective reduction of pulmonary vascular resistance (PVR) remains a therapeutic goal for the treatment of pulmonary hypertension, but current therapeutic options remain limited. Although the gas nitric oxide (NO) selectively dilates the pulmonary vascular bed, it requires special equipment for administration, has a short biologic half-life, and is potentially toxic. We hypothesized that stimulation of the NO pathway at the level of its second messenger, guanosine 3',5'-cyclic monophosphate (cGMP), by targeted pulmonary delivery of a membrane-permeable nonhydrolyzable cGMP analogue would cause selective pulmonary vasodilation. Pulmonary hypertension was induced in 21 pigs by the intravenous infusion of a thromboxane A2 analogue (9,11-dideoxy-9 alpha,11 alpha-epoxymethanoprostaglandin F2 alpha). Inhaled 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) lowered PVR in a time- and dose-dependent manner, with maximal effect achieved after 20 min. Compared with physiological saline control, 8-BrcGMP inhalation (3.0 micrograms/kg) lowered PVR by 25 +/- 3% (P < 0.01), whereas there was no significant decline in systemic vascular resistance (4 +/- 6%); mean pulmonary arterial pressure declined 13 +/- 3% (P < 0.01), whereas there was little change in mean arterial pressure; cardiac output increased 10 +/- 4% (P < 0.05). PVR did not decrease after inhalation of noncyclic 8-bromoguanosine 5'-monophosphate, indicating that stimulation of the NO-cGMP pathway beyond the level of NO results in pulmonary vasodilation independent of stimulation of purinergic receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

1 December 2004 in Critical Care Medicine
Verified
Journal Article
Closed access
SGSandeep Gangadharan
Sandeep Gangadharan
ASArthur Smerling
Arthur Smerling
GOGeorge Ofori-Amanfo
George Ofori-Amanfo
MMMarilyn Morris
Marilyn Morris
CSCharles Schleien
Charles Schleien
RMRalph Mosca
Ralph Mosca